

# Accepted Manuscript

Which evidence for a treat to target strategy in ulcerative colitis?

Aude Marchal Bressenot

PII: S1521-6918(18)30054-4

DOI: [10.1016/j.bpg.2018.05.001](https://doi.org/10.1016/j.bpg.2018.05.001)

Reference: YBEGA 1557

To appear in: *Best Practice & Research Clinical Gastroenterology*


Received Date: 14 March 2018

Revised Date: 8 April 2018

Accepted Date: 3 May 2018

Please cite this article as: Bressenot AM, Which evidence for a treat to target strategy in ulcerative colitis?, *Best Practice & Research Clinical Gastroenterology* (2018), doi: 10.1016/j.bpg.2018.05.001.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



## Which evidence for a treat to target strategy in ulcerative colitis?

Aude Marchal Bressenot<sup>1</sup>

<sup>1</sup> Department of pathology, University Hospital of Reims, 51100 Reims, France;

Corresponding author:

Marchal Bressenot Aude

University Hospital of Reims

Avenue du Général Koenig

51092 Reims

France

Phone: 33-03 26 78 42 95

amarchal@chu-reims.fr

Conflict of interest: Robarts clinical trials, Pfizer.

Download English Version:

<https://daneshyari.com/en/article/8720618>

Download Persian Version:

<https://daneshyari.com/article/8720618>

[Daneshyari.com](https://daneshyari.com)